创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

WANG Kaicheng, ZHANG Fangqing, YANG Xiaojun, ZHANG Huibin, ZHOU Jinpei. Progress in Small-Molecular Inhibitors Targeting c-Fms[J]. Progress in Pharmaceutical Sciences, 2018, 42(7): 517-526.
Citation: WANG Kaicheng, ZHANG Fangqing, YANG Xiaojun, ZHANG Huibin, ZHOU Jinpei. Progress in Small-Molecular Inhibitors Targeting c-Fms[J]. Progress in Pharmaceutical Sciences, 2018, 42(7): 517-526.

Progress in Small-Molecular Inhibitors Targeting c-Fms

  • Macrophage colony stimulating factor receptor (c-Fms), the product encoded by proto-oncogene fms, is a type Ⅲ receptor tyrosine kinase. c-Fms and its ligand CSF-1 play important roles in the proliferation, growth and differentiation of tumor-associated macrophages. c-Fms is abnormally expressed in a variety of malignant and inflammatory diseases. The CSF-1/c-Fms axis might be an effective approach to the treatment of malignant tumors. Many small molecular inhibitors targeting c-Fms are under research and clinical development. This article describes the mechanisms of c-Fms and its roles in tumor immunotherapy, and reviews the latest research progress in small-molecule inhibitors of c-Fms, so as to provide reference for follow-up studies.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return